Speaker
Description
3D bioprinting is emerging as one of the most disruptive technologies in modern medicine, offering the possibility to fabricate patient-specific tissues and organs for regenerative therapies, disease modelling, and drug testing. However, its translation from laboratory research to clinical application faces significant scientific, manufacturing, and regulatory challenges—particularly within the European Union’s complex legal framework. In addition to overcoming technical barriers such as establishing stable vascular networks, optimizing bioinks, and ensuring long-term construct functionality, developers must navigate a highly specific regulatory pathway. Within the EU, advanced bioprinted products incorporating living cells and structural biomaterials are often classified as combined Advanced Therapy Medicinal Products (cATMPs), subject to Regulation (EC) No 1394/2007 and related directives. This classification requires compliance with stringent Good Manufacturing Practice (GMP) standards, comprehensive preclinical safety and efficacy evaluation, and a centralized marketing authorization procedure through the European Medicines Agency (EMA). Early engagement with regulators via Scientific Advice is crucial to align development plans with EMA expectations, particularly regarding quality attributes, comparators, and clinical trial design. Our 12-year multidisciplinary program has addressed both technological and regulatory milestones in the development of the 3D-bioprinted Bionic Pancreas-ATMP®—from bioink formulation and vascularization strategies, through large-animal studies under GLP-like conditions, to the implementation of ISO 13485 standards. The Bionic Pancreas is now ready for first-in-human trials, supported by a comprehensive risk management plan and a regulatory strategy tailored for parallel EMA and FDA review. The path to clinical adoption of 3D-bioprinted organs in Europe is shaped not only by breakthroughs in tissue engineering but also by the ability to integrate these innovations into the ATMP regulatory framework. Mastering both domains is essential to transform 3D bioprinting from a disruptive concept into a safe, effective, and approved therapy for European patients. This presentation will outline the critical steps and lessons learned, helping other innovators avoid major hurdles along the way.
